MedTrace Logo

A Study of the Safety and Efficacy of EBV Specific T-cell Lines

NCT02580539 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-14

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.

Conditions

  • Epstein-Barr Virus Infections
  • Post-Transplant Lymphoproliferative Disorder
  • Lymphoma

Interventions

BIOLOGICAL

Group A

Peptide-stimulated T cells 2 x 10\^7/m\^2

BIOLOGICAL

Group B

Peptide-stimulated T cells per dose-escalation protocol

Sponsors & Collaborators

  • Dr. Jean-Sebastien Delisle, MD, PhD

    lead OTHER

Principal Investigators

  • Jean-Sebastien Delisle, MD,PhD · Maisonneuve-Rosemont Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02580539 on ClinicalTrials.gov